Recent data from the RECITE trial indicating that the thrombopoietin receptor agonist romiplostim ameliorates chemotherapy-induced thrombocytopenia offer hope for the first drug treatment for this condition. However, the ultimate goal is not to improve platelet counts but patient outcomes, and RECITE does not offer evidence of survival or quality-of-life benefits that truly matter to patients.
Access to this article via Institution of Civil Engineers Library is not available. Samkari, H.
et al. Romiplostim versus placebo for chemotherapy-induced thrombocytopenia.
N. Engl.
J. Med.
394 , 1061–1073 (2026). Nielson, C.
M., Bylsma, L. C., Fryzek, J.
P., Saad, H. A.
& Crawford, J. Relative dose intensity of chemotherapy and survival in patients with advanced-stage solid tumour cancer: a systematic review and meta-analysis.
Oncologist 26 , e1609–e1618 (2021). Raymond, E., Chaney, S.
G., Taamma, A. & Cvitkovic, E.
Oxaliplatin: a review of preclinical and clinical studies. Ann.
Oncol. 9 , 1053–1071 (1998).
André, T. et al.
Nature Reviews Clinical Oncology published a clinical update in Oncology on 09 Jun 2026.
The item focuses on RECITE this mantra in chemotherapy-induced thrombocytopenia: treat patients, not platelets.
Review the original article for the full source wording and details.